JAGSNPHARM

Unclassified

Jagsonpal Pharmaceuticals Limited

₹212.16

-2.15(-1.00%)
EMA 9: 216.79EMA 21: 219.11RSI: 42.8MACD: -2.80ATR: 7.63
Overlays
RSI (14)

Open

₹214.20

High

₹215.78

Low

₹212.00

Close

₹212.16

Volume

21,265

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) last closed at ₹212.16 on 17 Nov 2026, 19.8% below its 52-week high. Price is below both the 50-day and 200-day averages. Volume in the last session was light, at 0.3 times the 20-day average. The scanner currently flags Downtrend Alignment.

1 week

-2.4%

1 month

-2.8%

3 months

-9.2%

52-week high

₹264.5

-19.8% from high

52-week low

₹155

Volume vs 20-day

0.32×

Active signals

Move is measured from the close on the first day
Downtrend AlignmentBEARISH
Day 6 · since 06 Nov-0.5%

Signal history

Past five months · move is the close-to-close change while the signal was on
DatesSignalTypeLastedMove
30 Oct – 03 NovDowntrend AlignmentBEARISH3d+0.1%
28 OctRSI Momentum ExpansionBULLISH1d—
09 Oct – 22 OctDowntrend AlignmentBEARISH8d-6.5%
08 OctEMA Death Cross (9/21)BEARISH1d—
08 OctMACD Bearish CrossoverBEARISH1d—
07 OctMACD Bullish CrossoverBULLISH1d—
06 Oct – 07 OctStrong Uptrend AlignmentBULLISH2d+0.8%
06 Oct – 07 OctEMA Crossover (9/21)BULLISH2d+0.8%
05 OctDowntrend AlignmentBEARISH1d—
05 OctEMA Death Cross (9/21)BEARISH1d—
05 OctMACD Bearish CrossoverBEARISH1d—
25 Sept – 30 SeptStrong Uptrend AlignmentBULLISH4d-1.9%
25 SeptEMA Crossover (9/21)BULLISH1d—
25 SeptMACD Bullish CrossoverBULLISH1d—
24 Sept – 25 Sept20-Day High BreakoutBULLISH2d-0.7%
24 SeptRSI Momentum ExpansionBULLISH1d—
15 Sept – 23 SeptDowntrend AlignmentBEARISH7d-0.1%
15 SeptEMA Death Cross (9/21)BEARISH1d—
15 Sept – 16 SeptMACD Bearish CrossoverBEARISH2d+1.1%
03 Sept20-Day High BreakoutBULLISH1d—
03 Sept – 07 SeptStrong Uptrend AlignmentBULLISH3d-1.6%
03 SeptVolume BreakoutBULLISH1d—
20 Aug – 01 SeptStrong Uptrend AlignmentBULLISH8d+2.9%
17 Aug – 18 AugStrong Uptrend AlignmentBULLISH2d-1.1%
17 AugRSI Momentum ExpansionBULLISH1d—

Technical data for educational purposes only — not investment advice